Cargando…

合并糖尿病及治疗过程中血糖升高对弥漫大B细胞淋巴瘤患者预后的影响

OBJECTIVE: This study aims to investigate the clinical features and prognostic factors of patients with diffuse large B-cell lymphoma(DLBCL)and assess the prognostic value of diabetes mellitus(DM)and hyperglycemia during DLBCL treatment in DLBCL. METHODS: The clinical data of 481 newly diagnosed DLB...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071671/
https://www.ncbi.nlm.nih.gov/pubmed/33858047
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.02.011
_version_ 1783683760958472192
collection PubMed
description OBJECTIVE: This study aims to investigate the clinical features and prognostic factors of patients with diffuse large B-cell lymphoma(DLBCL)and assess the prognostic value of diabetes mellitus(DM)and hyperglycemia during DLBCL treatment in DLBCL. METHODS: The clinical data of 481 newly diagnosed DLBCL patients from January 1, 2009 to December 31, 2019 at Tianjin Medical University Cancer Institute and Hospital and Sun Yat-sen University Cancer Center were retrospectively collected, focusing on their blood glucose levels before and during treatment. Cox regression method was used for univariate analysis to assess prognostic factors, and the Kaplan-Meier method was used to draw survival curves to assess the prognostic value of DM and hyperglycemia during DLBCL treatment in patients with DLBCL. RESULTS: Eighty-two(17.0%)patients had DM before DLBCL diagnosis and treatment, and 88(18.3%)patients had at least one blood glucose increase during DLBCL treatment. Cox univariate analysis showed that age, Ann Arbor stage, international prognostic index, and DM were associated with overall survival(OS)and progression-free survival(PFS)(all P<0.05). The pairwise comparison between the two groups showed that the OS(P=0.001)and PFS(P<0.001)of patients with pre-existing DM were significantly worse than those of patients without abnormal blood glucose. Moreover, the OS(P=0.003)and PFS(P<0.001)of patients with hyperglycemia during DLBCL treatment were significantly worse than those of patients without abnormal blood glucose. No significant difference exists between patients with DM and patients with hyperglycemia during DLBCL treatment(OS, P=0.557; PFS, P=0.463). Additionally, patients with adequate glycemic control during chemotherapy had a better prognosis compared with patients with poor glycemic control(OS, P=0.037; PFS, P=0.007). CONCLUSION: DM is an important factor affecting the prognosis of patients with DLBCL. Moreover, hyperglycemia during treatment is related to the poor prognosis of patients with DLBCL.
format Online
Article
Text
id pubmed-8071671
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-80716712021-04-26 合并糖尿病及治疗过程中血糖升高对弥漫大B细胞淋巴瘤患者预后的影响 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: This study aims to investigate the clinical features and prognostic factors of patients with diffuse large B-cell lymphoma(DLBCL)and assess the prognostic value of diabetes mellitus(DM)and hyperglycemia during DLBCL treatment in DLBCL. METHODS: The clinical data of 481 newly diagnosed DLBCL patients from January 1, 2009 to December 31, 2019 at Tianjin Medical University Cancer Institute and Hospital and Sun Yat-sen University Cancer Center were retrospectively collected, focusing on their blood glucose levels before and during treatment. Cox regression method was used for univariate analysis to assess prognostic factors, and the Kaplan-Meier method was used to draw survival curves to assess the prognostic value of DM and hyperglycemia during DLBCL treatment in patients with DLBCL. RESULTS: Eighty-two(17.0%)patients had DM before DLBCL diagnosis and treatment, and 88(18.3%)patients had at least one blood glucose increase during DLBCL treatment. Cox univariate analysis showed that age, Ann Arbor stage, international prognostic index, and DM were associated with overall survival(OS)and progression-free survival(PFS)(all P<0.05). The pairwise comparison between the two groups showed that the OS(P=0.001)and PFS(P<0.001)of patients with pre-existing DM were significantly worse than those of patients without abnormal blood glucose. Moreover, the OS(P=0.003)and PFS(P<0.001)of patients with hyperglycemia during DLBCL treatment were significantly worse than those of patients without abnormal blood glucose. No significant difference exists between patients with DM and patients with hyperglycemia during DLBCL treatment(OS, P=0.557; PFS, P=0.463). Additionally, patients with adequate glycemic control during chemotherapy had a better prognosis compared with patients with poor glycemic control(OS, P=0.037; PFS, P=0.007). CONCLUSION: DM is an important factor affecting the prognosis of patients with DLBCL. Moreover, hyperglycemia during treatment is related to the poor prognosis of patients with DLBCL. Editorial office of Chinese Journal of Hematology 2021-02 /pmc/articles/PMC8071671/ /pubmed/33858047 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.02.011 Text en 2021年版权归中华医学会所有 https://creativecommons.org/licenses/by-nc-sa/3.0/This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
合并糖尿病及治疗过程中血糖升高对弥漫大B细胞淋巴瘤患者预后的影响
title 合并糖尿病及治疗过程中血糖升高对弥漫大B细胞淋巴瘤患者预后的影响
title_full 合并糖尿病及治疗过程中血糖升高对弥漫大B细胞淋巴瘤患者预后的影响
title_fullStr 合并糖尿病及治疗过程中血糖升高对弥漫大B细胞淋巴瘤患者预后的影响
title_full_unstemmed 合并糖尿病及治疗过程中血糖升高对弥漫大B细胞淋巴瘤患者预后的影响
title_short 合并糖尿病及治疗过程中血糖升高对弥漫大B细胞淋巴瘤患者预后的影响
title_sort 合并糖尿病及治疗过程中血糖升高对弥漫大b细胞淋巴瘤患者预后的影响
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071671/
https://www.ncbi.nlm.nih.gov/pubmed/33858047
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.02.011
work_keys_str_mv AT hébìngtángniàobìngjízhìliáoguòchéngzhōngxuètángshēnggāoduìmímàndàbxìbāolínbāliúhuànzhěyùhòudeyǐngxiǎng
AT hébìngtángniàobìngjízhìliáoguòchéngzhōngxuètángshēnggāoduìmímàndàbxìbāolínbāliúhuànzhěyùhòudeyǐngxiǎng
AT hébìngtángniàobìngjízhìliáoguòchéngzhōngxuètángshēnggāoduìmímàndàbxìbāolínbāliúhuànzhěyùhòudeyǐngxiǎng
AT hébìngtángniàobìngjízhìliáoguòchéngzhōngxuètángshēnggāoduìmímàndàbxìbāolínbāliúhuànzhěyùhòudeyǐngxiǎng
AT hébìngtángniàobìngjízhìliáoguòchéngzhōngxuètángshēnggāoduìmímàndàbxìbāolínbāliúhuànzhěyùhòudeyǐngxiǎng
AT hébìngtángniàobìngjízhìliáoguòchéngzhōngxuètángshēnggāoduìmímàndàbxìbāolínbāliúhuànzhěyùhòudeyǐngxiǎng
AT hébìngtángniàobìngjízhìliáoguòchéngzhōngxuètángshēnggāoduìmímàndàbxìbāolínbāliúhuànzhěyùhòudeyǐngxiǎng
AT hébìngtángniàobìngjízhìliáoguòchéngzhōngxuètángshēnggāoduìmímàndàbxìbāolínbāliúhuànzhěyùhòudeyǐngxiǎng
AT hébìngtángniàobìngjízhìliáoguòchéngzhōngxuètángshēnggāoduìmímàndàbxìbāolínbāliúhuànzhěyùhòudeyǐngxiǎng